887266-92-4Relevant articles and documents
SMALL MOLECULE PROSTAGLADIN TRANSPORT INHIBITORS
-
Paragraph 0161-0162, (2021/05/15)
The disclosure provides compounds of Formula 1, and the pharmaceutically acceptable salts thereof. The variables in Formula 1, e.g. X1-X5, A1, A2, and R1-R4 are described herein. Such compounds are useful as prostaglandin transport (PGT) inhibitors. The disclosure further includes pharmaceutical compositions comprising a compound of Formula 1 or salt thereof and methods of using compounds of Formula 1 and salts thereof to treat diseases and disorders mediated, at least in part, by prostaglandin levels or cyclooxygenase activity. Such diseases and disorders include painful and inflammatory conditions.
High-throughput screen for inhibitors of protein-protein interactions in a reconstituted heat shock protein 70 (Hsp70) complex
Taylor, Isabelle R.,Dunyak, Bryan M.,Komiyama, Tomoko,Shao, Hao,Ran, Xu,Assimon, Victoria A.,Kalyanaraman, Chakrapani,Rauch, Jennifer N.,Jacobson, Matthew P.,Zuiderweg, Erik R.P.,Gestwicki, Jason E.
, p. 4014 - 4025 (2018/03/25)
Protein-protein interactions (PPIs) are an important category of putative drug targets. Improvements in high-throughput screening (HTS) have significantly accelerated the discovery of inhibitors for some categories of PPIs. However, methods suitable for s
